Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Glioma cells deficient in urokinase plaminogen activator receptor expression are susceptible to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis.
|
11751520 |
2001 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Glioma cell proliferation was activated with TNF-α treatment and showed extreme sensitivity to the TNF receptor antagonist.
|
31691497 |
2020 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in established and primary glioma cell lines.
|
15844877 |
2002 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
TNF-α respecifies human mesenchymal stem cells to a neural fate and promotes migration toward experimental glioma.
|
21127499 |
2011 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis in malignant cells, including gliomas, and is currently in anticancer clinical trials.
|
21368892 |
2011 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) shows a strong apoptosis-inducing effect on a variety of cancer cells including glioma.
|
23338605 |
2013 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK), a member of the tumor necrosis factor superfamily, can stimulate glioma cell invasion via binding to fibroblast growth factor-inducible 14 (Fn14) and subsequent activation of the Rho guanosine triphosphatase family member Rac1.
|
23975833 |
2014 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioma cell invasion through induction of NF-κB-inducing kinase (NIK) and noncanonical NF-κB signaling.
|
25622756 |
2015 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has potent antitumor effects in glioma cell lines but has shown little clinical benefit for patients.
|
26142735 |
2015 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK), a member of the tumor necrosis factor (TNF) superfamily, can stimulate glioma cell invasion and survival via binding to fibroblast growth factor-inducible 14 (Fn14) and subsequent activation of the transcription factor NF-κB.
|
28103571 |
2017 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TNF-α stimulation further upregulated the expression of NF-κB1, STAT-6 in tandem with Ras-MEK signaling system in U87MG cells, which emphasized the possible involvement of these signaling hubs in the glioma microenvironment.
|
30839135 |
2019 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TNF-α and IL-1β expressions were significantly higher in the meningioma and glioma group in comparison to control group.
|
31653130 |
2019 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
ATM-NFκB axis-driven TIGAR regulates sensitivity of glioma cells to radiomimetics in the presence of TNFα.
|
23640457 |
2013 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Both compounds exhibited selective cytotoxicity against human glioma stem cells (GSCs) and induced caspase-3 dependent extrinsic apoptosis by increasing the expression of interleukin 1 (IL-1), tumor necrosis factor (TNF-α), and the cleaved caspase-3, while damaged the unlimited proliferation and self-renewal capacity of GSCs.
|
29486949 |
2018 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Expression of TROY (TNFRSF19), a member of the tumor necrosis factor (TNF) receptor family, increases with increasing glial tumor grade and inversely correlates with patient survival.
|
29117939 |
2018 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
FAT10 expression is highly up-regulated by pro-inflammatory cytokines IFN-γ and TNF-α in all cell types and tissues and it was also found to be up-regulated in many cancer types such as glioma, colorectal, liver or gastric cancer.
|
27393295 |
2016 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we investigated the sensitivity of a panel of glioma cell lines (U87, U251, U343, U373, MZ-54, and MZ-18) to apoptosis induced by the death receptor ligand tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL in combination with gamma irradiation, and TRAIL in combination with proteasome inhibitors (MG132 and epoxomicin).
|
18341587 |
2008 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here we show that in contrast to other cancer types, tumor necrosis factor (TNF)-alpha suppresses YKL-40 expression in glioma cell lines in a nuclear factor kappaB (NF-kappaB) dependent manner.
|
18708058 |
2008 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL13Rα2-CAR.CD28.ζ T cells proliferated, produced cytokines (IFNγ, TNF-α), and promoted a phenotypically pro-inflammatory glioma microenvironment by inducing a significant increase in the number of CD4<sup>+</sup> and CD8<sup>+</sup> T cells and CD8α<sup>+</sup> dendritic cells and a decrease in Ly6G<sup>+</sup> myeloid-derived suppressor cells (MDSCs).
|
29503195 |
2018 |
Glioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
In addition, resveratrol repressed nuclear factor kappa B (NF-κB) activation and down-regulated mRNA expression of urokinase plasminogen activator (uPA) and its receptor in TNF-α-treated glioma cells.
|
22199285 |
2011 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Injection of IL-22 increased the severity of glioma <i>in vivo</i> and higher expression levels of IL-6, IL-1β and tumor necrosis factor (TNF)-α were detected in the brain using ELISA following IL-22 injection.
|
28450947 |
2017 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Of various cytokines and growth factors, basic fibroblast growth factor (bFGF), tumor necrosis factor alpha (TNF-alpha), and interleukin 1 most potently enhanced VEGF mRNA levels of a glioma cell line, U251.
|
8910439 |
1996 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our therapeutic strategy was to use human bone marrow-derived mesenchymal stromal cells (hMSCs) as a cellular vehicle for the targeted delivery and local production of the biologic agent tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) at the glioma tumor site. hMSCs were transduced with a lentivirus expressing secretable TRAIL (S-TRAIL) and mCherry (red fluorescent protein).
|
19544410 |
2009 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Peripheral blood from 205 treatment-naïve patients with glioma (GBM = 145; non-GBM = 60) was obtained on the day of surgery to measure (i) circulating T-cells reacting to viral antigens and TAAs, in the presence or absence of cytokine conditioning with IL-2/IL-15/IL-21 or IL-2/IL-7, and (ii) serum cytokine levels (IL-4, IL-5, IL-6, TNF-α, IFN-γ and IL-17A).
|
30049387 |
2018 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Previous studies have shown that the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has significant apoptosis-inducing activity in some glioma cell lines, although many lines are either moderately or completely resistant, which has limited the therapeutic applicability of this agent.
|
21220502 |
2011 |